Protagen and GeneBio Sign Distribution Agreement for Modiro®
News May 30, 2008
Protagen AG and Geneva Bioinformatics (GeneBio) SA announced a distribution agreement that allows GeneBio to distribute Protagen’s Modiro, a software tool enabling rapid and automated detection of true post-translational modifications in MS/MS datasets.
Under the terms of the agreement, GeneBio will distribute the Modiro package on a global basis; at the same time, GeneBio and Protagen will collaborate closely in order to seamlessly link the Modiro functionalities to GeneBio’s Phenyx software platform for MS data analysis.
Post-translational protein modifications modulate the activity of many proteins and the in-depth analysis of these changes is of growing importance in the research and development of new drug candidates.
Modiro enables researchers to identify significantly more of these crucial modifications using existing mass-spectrometry data. In addition, the automated identification of PTMs by Modiro significantly reduces time and efforts in protein analyses.
Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s renowned software platform for the identification and characterization of proteins and peptides from mass spectrometry data.
The Phenyx platform is designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment via a customizable architecture and an user friendly interface.
“We are very excited about this collaboration with GeneBio and believe it will help to bring Modiro to wide range of new customers,” said Dr. Christoph Huls, CEO of Protagen.
“We are well aware of the reputation of both GeneBio and Phenyx within the industry and feel that our combined efforts will help to establish Modiro as the gold-standard for PTM analysis. In addition, we look forward to working with the GeneBio team in order to enhance both the Modiro and Phenyx platform.”
Massachusetts General Hospital (MGH) researchers have found that extracellular RNA (exRNA) in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.READ MORE
Is there a link between differences in IQ test performance and the activity of certain genes? Researchers have shown that modifications in the structure of a specific gene have a negative impact on individual test performance. This suggests that environmentally-induced epigenetic changes to our genetic material have a greater impact on intelligence than previously thought.